|
|
Correction Correction: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern SwedenHeidi Kokkonen1, Martin Johansson1, Lena Innala1, Erik Jidell2 and Solbritt Rantapää-Dahlqvist1 1Department of Rheumatology, University Hospital, SE-901 85 Umeå, Sweden 2Department of Transfusion Medicine, University Hospital, SE-901 85 Umeå, Sweden
Arthritis Research & Therapy 2007, 9:403doi:10.1186/ar2312 See related research article by Kokkonen et al., http://arthritis-research.com/content/9/3/R56 The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/9/5/403
© 2007 BioMed Central Ltd CorrectionAfter publication of our recent article [1], we noticed an error in Table 6 'Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies'. Under the heading of 'Anti-CCP antibody-positive', the first line should read 'HLA-shared epitope-negative', and the second line should read 'HLA-shared epitope-positive'. Similarly, under the heading 'Anti-CCP antibody-negative', the first line should read 'HLA-shared epitope-negative' and the second line should read 'HLA-shared epitope-positive'. The correct table is given here as Table 1 (a corrected version of Table 6 [1]). Table 1. Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies References
Have something to say? Post a comment on this article! |
|
|
|
 |  | Log on / register BioMed Central home | Journals A-Z | Feedback | Support | My details |
home | issues | articles | reports | supplements | weblinks | conferences | search | information | subscribe | my details |
on Google Scholar
author email
corresponding author email|
|
| © 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media. |